Edwards Lifesciences (NYSE:EW) VP Larry L. Wood sold 6,300 shares of Edwards Lifesciences stock in a transaction on Monday, April 16th. The shares were sold at an average price of $138.97, for a total transaction of $875,511.00. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.
Shares of EW stock opened at $137.09 on Friday. Edwards Lifesciences has a 12 month low of $97.63 and a 12 month high of $143.22. The company has a current ratio of 1.80, a quick ratio of 1.41 and a debt-to-equity ratio of 0.15. The firm has a market capitalization of $29,302.51, a price-to-earnings ratio of 36.08, a PEG ratio of 2.04 and a beta of 0.58.
Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Thursday, February 1st. The medical research company reported $0.94 EPS for the quarter, topping analysts’ consensus estimates of $0.91 by $0.03. Edwards Lifesciences had a net margin of 18.11% and a return on equity of 27.78%. The firm had revenue of $888.50 million for the quarter, compared to analyst estimates of $868.45 million. During the same quarter in the previous year, the business posted $0.75 EPS. The firm’s revenue was up 15.7% compared to the same quarter last year. sell-side analysts forecast that Edwards Lifesciences will post 4.53 EPS for the current fiscal year.
Hedge funds have recently modified their holdings of the business. Cerebellum GP LLC acquired a new stake in shares of Edwards Lifesciences in the 4th quarter valued at about $128,000. Resources Investment Advisors Inc. raised its stake in shares of Edwards Lifesciences by 66.0% in the 4th quarter. Resources Investment Advisors Inc. now owns 1,170 shares of the medical research company’s stock valued at $132,000 after purchasing an additional 465 shares in the last quarter. Exane Derivatives raised its stake in shares of Edwards Lifesciences by 381.3% in the 4th quarter. Exane Derivatives now owns 1,213 shares of the medical research company’s stock valued at $137,000 after purchasing an additional 961 shares in the last quarter. Lake Street Advisors Group LLC acquired a new stake in shares of Edwards Lifesciences in the 4th quarter valued at about $201,000. Finally, Captrust Financial Advisors acquired a new stake in shares of Edwards Lifesciences in the 4th quarter valued at about $204,000. Hedge funds and other institutional investors own 82.98% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This news story was originally published by Week Herald and is owned by of Week Herald. If you are accessing this news story on another domain, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The correct version of this news story can be accessed at https://weekherald.com/2018/04/21/insider-selling-edwards-lifesciences-ew-vp-sells-875511-00-in-stock.html.
About Edwards Lifesciences
Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic heart valves and related delivery systems for the nonsurgical replacement of heart valves.
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.